{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:56:34Z","timestamp":1791932194875,"version":"4.3.4"},"reference-count":23,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Garrod Association, Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Lipoprotein lipase (LPL) deficiency is a genetic condition. Affected individuals typically develop symptoms related to severe and persistent hypertriglyceridemia, such as abdominal pain and recurrent pancreatitis, before 10 years of age. No pharmacological treatment sustainably lowering triglycerides (TGs) in LPL deficiency patients has been proven to be effective. This study investigated whether a long-chain triglyceride (LCT)-restricted, medium-chain triglyceride (MCT)-supplemented diet enables a meaningful reduction in TGs and reduces LPL-related symptoms in children with LPL deficiency. Methods: A single-center retrospective case series study of LPL deficiency patients treated at the Hospital of Sick Children between January 2000 and December 2022 was carried out. Data, extracted from hospital charts, included demographics, diagnosis confirmation, clinical and imaging observations, and biochemical profiles. Results: Seven patients with hypertriglyceridemia &gt; 20 mmol\/L suspected of an LPL deficiency diagnosis were included. Six patients had a confirmed molecular diagnosis of LPL deficiency, and one had glycogen storage disease type 1a (GSD1a). Clinical presentation was at a median of 30 days of age (range 1\u2013105), and treatment start, excluding one late-treated patient, was at a median of 42 days (range 2\u2013106). The observation and treatment period of the LPL patients was 48.0 patient years (median 7.1, range 4.3\u201315.5). The LCT-restricted and MCT-supplemented diet led to an immediate drop in TGs in six out of six LPL patients. TGs improved from a median of 40.9 mmol\/L (range 11.4\u2013276.5) pre-treatment to a median of 12.0 mmol\/L (range 1.1\u201336.6) during treatment, total cholesterol from 7.6 mmol\/L (4.9\u201327.0) to 3.9 mmol\/L (1.7\u20138.2), and pancreatic lipase from 631 IU\/L (30\u20131200) to 26.5 IU\/L (5\u2013289). In 48 patient years, there was only one complication of pancreatitis and no other disease-specific manifestations or complications. Catch-up growth was observed in one late-treated patient. All patients maintained normal growth and development. As expected, the diet failed to treat hypertriglyceridemia in the GSD1a patient. Conclusions: The dietary restriction of LCT in combination with MCT supplementation as long-term management of pediatric patients with LPL deficiency was feasible, well tolerated, and clinically effective in reducing TG levels and in preventing LPL-related complications.<\/jats:p>","DOI":"10.3390\/nu15163535","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T10:33:23Z","timestamp":1691750003000},"page":"3535","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-Term Treatment of Lipoprotein Lipase Deficiency with Medium-Chain Triglyceride-Enriched Diet: A Case Series"],"prefix":"10.3390","volume":"15","author":[{"given":"Liali","family":"Aljouda","sequence":"first","affiliation":[{"name":"Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nagy","sequence":"additional","affiliation":[{"name":"Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8491-1095","authenticated-orcid":false,"given":"Andreas","family":"Schulze","sequence":"additional","affiliation":[{"name":"Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada"},{"name":"Department of Pediatrics, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/2050640618755002","article-title":"Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management","volume":"6","author":"Amodio","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: An open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers","year":"2015","journal-title":"Lipids Health Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: Thirteen years\u2019 treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MOL.0000000000000231","article-title":"Novel therapeutics in hypertriglyceridemia","volume":"26","author":"Gryn","year":"2015","journal-title":"Curr. Opin Lipidol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17512433.2018.1480368","article-title":"Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome","volume":"11","author":"Chaudhry","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_8","first-page":"1","article-title":"Management of severe hypertriglyceridemia due to lipoprotein lipase deficiency in children. Endocrinol","volume":"2019","author":"Poon","year":"2019","journal-title":"Diabetes Metab. Case Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2014Current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12098-020-03305-z","article-title":"Lipoprotein Lipase Deficiency","volume":"88","author":"Kuthiroly","year":"2021","journal-title":"Indian J. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ymgme.2020.10.001","article-title":"Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach","volume":"131","author":"Sowa","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/mgme.2001.3170","article-title":"Quantitative determination of plasma c8-c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders","volume":"73","author":"Lagerstedt","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10545-009-1126-8","article-title":"Treatment recommendations in long-chain fatty acid oxidation defects: Consensus from a workshop","volume":"32","author":"Spiekerkoetter","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-2275(20)32399-3","article-title":"Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis","volume":"41","author":"Clee","year":"2000","journal-title":"J. Lipid Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199609193351203","article-title":"Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene","volume":"335","author":"Benlian","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/302234","article-title":"Linkage of low-density lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency","volume":"64","author":"Hokanson","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/0004563215590451","article-title":"Lipoprotein lipase and atherosclerosis","volume":"52","author":"Kobayashi","year":"2015","journal-title":"Ann. Clin. Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12944-022-01631-z","article-title":"Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia","volume":"21","author":"Paragh","year":"2022","journal-title":"Lipids Health Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2478\/bjmg-2021-0013","article-title":"A Case of Glycogen Storage Disease Type 1a Mimicking Familial Chylomicronemia Syndrome","volume":"24","author":"Olgac","year":"2021","journal-title":"Balkan J. Med. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1742-1241.2011.02867.x","article-title":"New lipid-lowering drugs: An update","volume":"66","author":"Wierzbicki","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/hum.2018.007","article-title":"Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions","volume":"29","author":"Kassner","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Burns-Whitmore, B., Froyen, E., Heskey, C., Parker, T., and San Pablo, G. (2019). Alpha-Linolenic and Linoleic Fatty Acids in the Vegan Diet: Do They Require Dietary Reference Intake\/Adequate Intake Special Consideration?. Nutrients, 11.","DOI":"10.3390\/nu11102365"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/16\/3535\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:31:20Z","timestamp":1760128280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/16\/3535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":23,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["nu15163535"],"URL":"https:\/\/doi.org\/10.3390\/nu15163535","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}